Navigation Links
Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass., April 13, 2007 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced today that results of preclinical studies with its lead product candidate, XMT-1001, will be presented in two posters at the 2007 Annual Meeting of the American Association of Cancer Research (AACR) taking place April 14-18th in Los Angeles, CA. Full text of the abstracts can be viewed online at the AACR website at http://www.AACR.org.

The presentation schedule is as follows:

Abstract #781 "XMT-1001, a novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model" will be presented in a poster session on Sunday, April 15th from 8:00 am - 12:00 pm. Alex Yurkovetskiy and Russell C. Petter are the presenting authors.

Abstract #4723 "Pharmacokinetics of a novel camptothecin conjugate (XMT- 1001) in the rat and dog" will be presented in a poster session on Tuesday, April 17th from 1:00 - 5:00 pm. Ullrich Schwertschlag and Alex Yurkovetskiy are the presenting authors.

About XMT-1101

XMT-1001 is Mersana's most advanced Fleximer(R)-based product candidate. It utilizes a novel, dual release mechanism to liberate a camptothecin prodrug, which is then converted within cells into camptothecin, a DNA topoisomerase I inhibitor. In preclinical studies, XMT-1001 was better tolerated and more efficacious than either camptothecin or irinotecan in models of human cancer, showing extended plasma half-life and high concentrations in tumor tissue.

About Fleximer Technology

Fleximer(R) technology improves the therapeutic index of cytotoxic compounds useful as anti-cancer agents by uniquely combining biodegradability with "biological stealth" properties, making Fleximer(R) materials and their conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are characterized
'"/>




Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:2/27/2015)... 2015  Acsis Inc., the market leader for supply ... that John DiPalo , Acsis, Chief Strategy Officer, ... Chain Executive 2015 Provider Pro to Know. The ... to help prepare their companies, and customers, supply chains ... year,s list of Provider Pros to Know is featured ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
(Date:2/27/2015)... February 27, 2015 Report Details ... showing you trends, R&D progress, and predicted revenues ,Where ... What are the commercial prospects for this market and ... revenues and other trends to 2025, discussing data, opportunities ... you assess regenerative medicine : cell-based therapies that ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... 2012  Boehringer Ingelheim will present results from LUX-Lung ... investigating afatinib in patients with stage IIIB or ... epidermal growth factor receptor (EGFR) mutation (EGFR M+), ... Society of Clinical Oncology (ASCO) in Chicago, June ...
... May 16, 2012  Leading events organiser UBM Conferences ... announced details of the forthcoming CPhI Extractables and Leachables ... 2pm IST/9:30am GMT/4:30pm CST. The free to attend webinar ... extractables and leachables and during drug development, in addition ...
Cached Medicine Technology:Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 2Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 3Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 4Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 5Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 6Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012 7Global Webinar Focuses on Considerations for Extractables and Leachables 2
(Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 In ... Duncan Fletcher of Game Change Athlete ... Shannon Leinert about the benefits of athlete development and ... some of the unique challenges that athletes face and ... and future success. , Fletcher became involved in athlete ...
(Date:2/28/2015)... February 28, 2015 With their commitment ... has added an additional exercise to their already robust ... exercise is most commonly known as, is often performed ... Pulls” are executed in a relatively safe manner and ... strength levels. The full description of “Rope Pulls” is ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... is offering a new special. Throughout all of ... , This service can help ... problems and pain. Patients may notice certain symptoms that ... relining. These symptoms include: , 1.    Pain, clicking, and ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
... , WEDNESDAY, Oct. 27 (HealthDay News) -- With ... expert offers breast cancer survivors some guidance on what ... Karen Syrjala, director of biobehavioral sciences and co-director ... Research Center in Seattle, touches upon both the lingering ...
... The brain,s inner network becomes increasingly more efficient as ... measures, a joint study from the Ecole Polytechnique Fdrale ... in collaboration with Harvard Medical School, has verified these ... the PNAS early online edition last week, the soon-to-be-released ...
... genes respond to hormonal changes and inflammation has been ... a five-year study. The research programme at the ... (BRC) is led by Professor Julian Davis, a consultant ... University of Manchester,s Developmental Biomedicine Research Group. He ...
... , TUESDAY, Oct. 26 (HealthDay News) --Middle-aged adults ... as a result of radiation exposure as younger adults ... thought to be more sensitive to the long-term impact ... runs counter to some previous research suggesting that as ...
... Institute in Melbourne, Australia, has been awarded a Victorian Cancer ... and highly lethal form of ovarian cancer. Epithelial ovarian ... the ovary, accounts for 90 per cent of ovarian tumours. ... research has revealed that it may start in cells outside ...
... though the cancer-treatment agent cetuximab is not considered effective ... research indicates that patients with colorectal cancer not responding ... who were treated with cetuximab had longer overall and ... a study in the October 27 issue of ...
Cached Medicine News:Health News:Women Urged to Reclaim Their Life After Breast Cancer 2Health News:The brain's journey from early Internet to modern-day fiber optics -- all in 1 lifetime 2Health News:Manchester team wins $1.9 million grant for 'cell control' study 2Health News:Cancer Risk From Radiation Doesn't Fade With Age 2Health News:VCA fellowship funding to extend ovarian cancer research 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: